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Aberrant methylation of CpG islands located at or near gene promoters is associated with inactivation of gene expression during
tumour development. It is increasingly recognised that such epimutations may occur at a much higher frequency than gene mutation
and therefore have a greater impact on selection of subpopulations of cells during tumour progression or acquisition of resistance to
anticancer drugs. Although laboratory-based models of acquired resistance to anticancer agents tend to focus on specific genes or
biochemical pathways, such ‘one gene:one outcome’ models may be an oversimplification of acquired resistance to treatment of
cancer patients. Instead, clinical drug resistance may be due to changes in expression of a large number of genes that have a
cumulative impact on chemosensitivity. Aberrant CpG island methylation of multiple genes occurring in a nonrandom manner during
tumour development and during the acquisition of drug resistance provides a mechanism whereby expression of multiple genes
could be affected simultaneously resulting in polygenic clinical drug resistance. If simultaneous epigenetic regulation of multiple genes
is indeed a major driving force behind acquired resistance of patients’ tumour to anticancer agents, this has important implications for
biomarker studies of clinical outcome following chemotherapy and for clinical approaches designed to circumvent or modulate drug
resistance.
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With the increasing variety of options for the treatment of cancer,
it is becoming essential that the choice of anticancer therapy, or
optimal combination of therapies, is based not only on conven-
tional clinical/pathological criteria but also on the molecular
phenotype of the tumour. Many solid tumours are initially
sensitive to chemotherapy, but the vast majority will recur or
progress with ultimate failure of conventional cytotoxic che-
motherapy treatment. In general, novel experimental therapies are
first examined for efficacy in patients that have failed standard
treatments and whose tumours have acquired resistance to
cytotoxic drugs. The pattern of gene expression of a tumour that
no longer responds to conventional treatment will be very different
from that of the tumour at presentation due to selection of drug-
resistant subpopulations. However, we know very little about the
molecular characteristics of tumours after conventional treatment
failure or the underlying mechanisms that drive the acquisition of
drug resistance (Agarwal and Kaye, 2003).
Laboratory-based studies have identified a wide variety of
biochemical pathways and many hundred genes that can
potentially influence response to treatment in tumour cells.
Early work in drug resistance identified genes such as MDR1
(P-glycoprotein) (Gottesman, 1993) and p53 (Lowe et al, 1993) as
crucial in determining drug resistance in experimental models of
in vitro cell lines or transgenic mice. However, there is relatively
little evidence that, individually, these mechanisms are able to
predict treatment outcome in a manner that is comparable to
known prognostic markers such as stage, performance status and
histological grade (Agarwal and Kaye, 2003; Hall et al, 2004). The
variability in quality of prognostic and predictive biomarker
studies can make reaching a consensus on the value of a given
marker challenging and recent recommendations have emphasised
the need for appropriate design and reporting of biomarker studies
(http://www.cancerdiagnosis.nci.nih.gov/assessment/progress/
progress/remark.html). Furthermore, response to treatment is only
one factor influencing clinical outcome, numerous other tumour
characteristics, such as capacity for invasion/metastasis or escape
from the immune response, will also have an impact and may do
so irrespective of the therapies used, diluting any association
between a marker of drug resistance and clinical outcome. For
instance, in the case of ovarian cancer, one of the strongest
prognostic markers associate with time to progression of a tumour
after treatment is the number of infiltrating T cells (Zhang et al,
2003). However, while these factors may confound the analysis
of drug-resistance mechanisms, it is also becoming apparent that
‘one gene:one outcome’ is an oversimplification for acquired
resistance to treatment of cancer patients. Thus, it seems
increasingly likely that clinical drug resistance is due to polygenic
expression changes involving multiple mechanisms rather than to
the alteration of a single pathway or gene.
An analogy can be made between clinical drug-resistance genes
and cancer susceptibility genes. Cancer susceptibility genes such as
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www.bjcancer.comretinoblastoma (RB1) and adenomatois polyposis coli (APC) were
originally identified as rare, mutant alleles that significantly
increase the risk of cancer when inherited through the germ line.
More recently, it has been argued that the greater part of cancer
predisposition may be due to a combination of weak genetic
variants at many different loci rather than to single high
penetrance genes (Balmain et al, 2003). Similarly, the combination
of weak effects on drug resistance due to expression changes at
many genes may be more significant than the effect of any single
gene. Since most cytotoxic drugs have a low therapeutic index,
additive effects of multiple low fold changes in drug resistance may
be sufficient to cause clinical treatment failure. However,
identification and evaluation of multiple, small additive effects
on clinical outcome following chemotherapy will require robust
and novel statistical and computational approaches that allow
nonrandom clustering of effects to be identified. In order to
avoid the pitfalls inherent in analysing high-dimensional data
sets such as multiple testing and limited sample size, large-scale
prospective clinical studies are required. In addition, it may
be more informative to study tumours longitudinally, as they
acquire resistance during treatment rather than simply sampling
tumours at presentation and to use surrogate end points more
specific to drug resistance, such as response rather than overall
survival.
GENETIC VS EPIGENETIC ALTERATIONS OF
RESISTANCE GENES
At the time of writing, we have been unable to identify any study of
clinical material that has identified acquisition of a p53 mutation
during treatment of a given patient and similarly gene amplifica-
tion of MDR1, although widely observed in highly resistant cell
lines, is only rarely observed following chemotherapy. Therefore,
although mutations in genes such as MDR1 and p53 confer drug
resistance in vitro and in animal models, and they may have a role
in inherent resistance, there is little evidence that such genetic
changes have a role in acquired clinical resistance following
anticancer therapy.
It is clear that changes in gene expression do occur following
chemotherapy leading to the question, if not gene mutations, what
are the mechanisms leading to changes in gene expression? The
answer may lie in the increasing evidence that epigenetic changes
can be a crucial driving force behind the acquisition of drug
resistance (Teodoridis et al, 2004). Indeed studies of drug-resistant
cell line models have shown that multiple changes in methylation
of CpG islands and epigenetic regulation occur following drug
selection (Wei et al, 2003).
Epigenetics changes are heritable changes in gene expression
that do not involve an alteration in the DNA sequence. Within the
nucleus, DNA is packaged, together with histone proteins, into
a higher order structure known as chromatin. Interpretation
of genetic information coded within the DNA is regulated by
mechanisms that involve stable and heritable modifications of
DNA and histones. These modifications include methylation of
DNA at CpG dinucleotides and methylation, acetylation and
phosphorylation of histones. Changes in the patterns of these
modifications are associated with chromatin remodelling and
can result in changes in gene expression through increasingly
understood mechanisms (Lachner et al, 2003).
DNA methylation involves the transfer of a methyl group to the
carbon-5 position of cytosine residues, and occurs almost
exclusively at cytosines that are followed by a guanine (CpG
dinucleotides). CpG dinucleotides are relatively rare in the bulk of
the genome and are nearly always methylated, but small stretches
of DNA occur that are rich in CpG dinucleotides, so called CpG
islands. These are usually unmethylated in normal cells and are
often associated with the promoter regions of genes (Hendrich and
Bird, 2000). Methylation of cytosines within these islands is
associated with binding of methyl-binding domain (MBD)
proteins, recruitment of histone deacetylases (HDACs) and histone
methyltransferases, histone modification, chromatin condensation
and transcriptional inactivation of the associated genes. A large
number of genes where aberrant methylation of CpG islands within
their promoters is associated with gene inactivation have now been
identified in tumours (for methods of analysing CpG island
methylation, see Box 1). These include genes involved in all aspects
of tumour development and also in response to treatment
Box 1 Methods for detecting CpG island methylation
Methods for the analysis of CpG-island methylation are available both genome-wide and at the single gene level. Restriction landmark genomic scanning (RLGS) is
performed by digesting genomic DNA with a methylation-sensitive restriction enzyme, end labelling of the resulting DNA fragments and subsequent digestion with two
different restriction enzymes and 2-dimensional gel electrophoresis (Costello et al, 2000). Comparison of signal intensities between tumour and normal DNA after
autoradiography allows estimation of the number of aberrantly methylated CpG islands in tumours, and individual aberrantly methylated CpG islands can be identified
by sequencing. Differential methylation hybridisation (DMH) is an alternative means of examining genome-wide methylation patterns that uses restriction digestion of
genomic DNA and ligation to linkers (Huang et al, 1999), followed by digestion with a methylation-sensitive restriction enzyme such as BstUI, PCR amplification and
hybridisation to CpG-rich DNA sequences (representing putative CpG islands). Comparison to hybridisation signals obtained from undigested linker-ligated DNA
allowed the identification of aberrantly methylated CpG islands. Methylation sensitive-representational difference analysis (MS-RDA) uses genomic tester and driver
DNA samples digested with the methylation-sensitive restriction enzyme HpaII (Ushijima et al, 1997). Sequences that are specific for the tester amplicon are
subsequently enriched by repeated cycles of subtractive hybridisations.
Several methods for the analysis of the methylation status of individual CpG islands utilise bisulphate treatment of DNA, which has been described in detail (Grunau
et al, 2001; Warnecke et al, 2002). Bisulphite treatment of DNA converts unmethylated cytosines into uracil but does not affect methylated cytosines. A difference in
methylation is thus converted into a difference in sequence. A widely used method for analysing the methylation status of specific sequences is methylation-specific PCR
(MSP) (Herman et al, 1996). Methylation-specific PCR is performed using primers specific for either unmethylated or methylated sequences, thereby allowing the
detection of the respective methylation state. Among the advantages of MSP are its easy detection due to its gain-of-signal character and its high sensitivity, allowing the
detection of as little as 0.1% methylation in a DNA sample (Herman et al, 1996). The MethyLight technique also involves bisulphite modification. Fluorescence-based
PCR is then performed with primers that either overlap CpG methylation sites or that do not overlap any CpG dinucleotides. Sequence discrimination can occur either
at the level of the PCR amplification process or at the level of the probe hybridisation process or both (Eads et al, 2000). Combined restriction analysis (COBRA) uses
primers that amplify the template irrespective of its methylation state (Xiong and Laird, 1997). The PCR product should therefore be heterogeneous and reflect the
various methylation states present in the template. Discrimination of methylation states is achieved by restriction digest using a restriction site whose presence after
bisulphite modification depends on the methylation state of the DNA. Combined restriction analysis allows the quantification of the methylation, but its disadvantage is
that the methylation of one CpG site is not necessarily representative for the other CpG sites in the analysed sequence. The highest accuracy of methylation density in a
region of DNA is achieved by bisulphite sequencing. As in COBRA, the modified DNA is amplified irrespective of its methylation state, but subsequently the amplicon is
subcloned and sequenced. This not only allows detection of methylation with a single-nucleotide resolution but also gives information about the distribution of
methylated cytosines within individual DNA molecules. The disadvantage is that bisulphite sequencing is relatively labour-intensive.
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hMLH1, BRCA1 and E-CADHERIN, aberrant methylation of CpG
islands is a far more frequent mechanism of gene inactivation in
sporadic tumours than gene mutation or deletion.
Gene inactivation by DNA methylation can occur at a rate
several orders of magnitude higher than inactivation of the same
gene by mutation (Bhattacharyya et al, 1994). So, if inactivation of
a gene is an important mechanism driving the acquisition of drug
resistance, the probability of this occurring by methylation and
being selected for during chemotherapy is much more likely than it
occurring by mutation. It has also been suggested that some
tumours may acquire a CpG island methylator phenotype, that is,
concurrent methylation of genes occurring in a nonrandom
manner (Toyota et al, 1999). Cellular acquisition of a methylator
phenotype could give cells a higher probability of cell transforma-
tion during carcinogenesis, as has been proposed for gene muta-
tions and the mutator phenotype (Loeb, 1994). Disruption of the
cellular processes involved in methylation could lead to concurrent
hypermethylation of multiple genes, including tumour suppressor
genes, and as a result lead to oncogenic transformation. A possible
consequence of this would be that in a tumour with a methylator
phenotype there would also be a higher probability of multiple
drug-resistance/sensitivity genes becoming methylated, with asso-
ciated changes in gene expression. Thus, epigenetic silencing may
occur fortuitously during tumour development and only confer an
advantage to tumour cells when they are treated with chemo-
therapy or radiotherapy. However, the existence of a distinct
methylator phenotype has been challenged, since a bimodal
distribution of methylation frequency has not been seen in the
same way as observed for gene mutation in tumour cells with the
mutator phenotype (Yamashita et al, 2003; Anacleto et al, 2005).
Nevertheless, the vast majority of tumours, if not all, have
aberrant DNA methylation at CpG islands and epigenetic silencing
of the associated genes. Patterns of CpG island methylation differ
between and within tumour types in a manner that suggests that
methylation is not a random process (Costello et al, 2000; Esteller
et al, 2001; Wei et al, 2002). Epigenetic inheritance of transcription
patterns has been implicated in the control of cell proliferation
during development, as well as in stem-cell renewal and cancer
(Valk-Lingbeek et al, 2004). However, the mechanisms and
selective processes that give rise to specific methylation patterns
in tumours remain unclear and are likely to be complex. Changes
in cell metabolism (Paz et al, 2002), ‘epigenetic drift’(Egger et al,
2004) and ageing (Richardson, 2002) have all been proposed. For
instance, there is a global decrease in global 5 methlycytosine levels
in DNA as cells age which is similar to that observed in many
tumours (Richardson, 2002). At the same time, localised hyper-
methylation occurs at some CpG islands. In a restriction landmark
genome scanning study of CpG island methylation in T
lymphocytes from newborn, middle age and elderly subjects, only
29 of more than 2000 loci examined were found to alter
methylation with ageing, with 23 increasing methylation, and six
decreasing. The same subset also changed methylation status with
age in the oesophagus, lung and pancreas, but in variable
directions (Tra et al, 2002). Thus, age-specific methylation also
occurs in a nonrandom manner suggesting a tightly controlled
process. What ever the process, it seems likely that epigenetic
changes regulating gene expression offer a more rapid means by
which tumour cells can adapt to new environment such as
cytotoxic drug therapy than genetic change and because such
changes are heritable they can be passed on to daughter cells
without the need for continuous selection pressure producing
persistent acquired resistance.
EVIDENCE FOR THE ROLE OF EPIGENETIC
MECHANISMS IN DRUG RESISTANCE
Altered expression of genes involved in apoptosis and DNA repair
may play an important role in determining response to treatment
and there are many examples of such genes being methylated in
tumours (see Table 1). However, methylation of individual genes
may have opposing effects on drug sensitivity. For instance,
methylation of DNA repair genes such as MGMT and FANCF may
lead to inactivation of DNA repair and confer chemosensitivity,
while methylation and epigenetic silencing of proapoptotic genes
such as hMLH1 and APAF1 would confer resistance (Esteller et al,
2000; Soengas et al, 2001; Taniguchi et al, 2003; Teodoridis et al,
2004).
Table 1 Examples of genes associated with drug resistance
Gene Function Evidence for role in drug sensitivity Reference
Apaf 1 Proapoptotic, binds and promotes
caspase 9 activation
Methylation in melanoma cells can be reversed by DNMT inhibitors and this is
associated with increased sensitivity to doxorubicin
Soengas et al (2001)
Caspase 8 Proapoptotic Frequently methylated in tumours. Reversal of methylation associated with
increased sensitivity to doxorubicin, etoposide and cisplatin in Ewings sarcoma,
neuroblastoma, medulloblastoma and melanoma cell lines
Fulda et al (2001)
hMLH1 DNA mismatch repair protein Methylation and loss of expression associated with resistance to cisplatin in cell
lines, which can be reversed by demethylation with decitabine. Increased
frequency of methylation after chemotherapy. Acquisition of hMLH1
methylation during chemotherapy is independently associated with poor overall
survival in ovarian patients
Gifford et al (2004)
FancF Activates DNA repair complex
containing BRCA1, and BRCA2 loss
cause a decreased ability to repair
chemotherapy-induced damage
Methylation observed in cells with a defective BRCA2 pathway and increased
sensitivity to cisplatin. Demethylation of FANCF with decitabine reduced
sensitivity towards cisplatin in these cell line models
Taniguchi et al (2003)
MGMT Removes mutagenic alkyl-groups
from the O6-position of guanine
Methylation and associated loss of expression correlates with response to
temozolamide and BCNU in primary gliomas and overall and progression-free
survival in patients with diffuse large B-cell lymphoma treated with
cyclophosphamide-containing regimens
Paz et al (2004)
MCJ Unknown Methylation associated with poor response to therapy and poor overall survival
in ovarian patients
Strathdee et al (2005)
ERb Methylated in 50% of invasive breast cancers. Methylation of ERb less frequent
and expression rate was higher in tamoxifen-resistant compared to control
tumours
Chang et al (2005)
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be necessary for engagement of a variety of downstream cellular
responses to alkylating agents and cisplatin-induced DNA damage
(Papouli et al, 2004). Re-expression of hMLH1 in isogenic model
systems has demonstrated that loss of hMLH1 expression confers
resistance to alkylating agents and cisplatin. The frequency of
hMLH1 methylation in ovarian tumours increases after chemo-
therapy (Strathdee et al, 1999). Tumours frequently release DNA
which can subsequently be isolated from plasma samples (Johnson
and Lo, 2002). Genetic and epigenetic changes that are present in
the tumour can be detected in tumour DNA isolated from plasma.
Analysis of hMLH1 methylation in tumour DNA isolated from
plasma of patients with ovarian cancer before chemotherapy and at
relapse showed that 25% of patients acquired hMLH1 methylation
during chemotherapy and acquisition of hMLH1 methylation was
independently associated with poor overall survival, potentially as
a result of poor response to subsequent lines of chemotherapy
(Gifford et al, 2004).
In contrast to proapoptotic genes, loss of expression of DNA
repair genes may be associated with increased sensitivity to
chemotherapy. The DNA repair enzyme MGMT (O6 methyl
guanine methyltransferase) removes mutagenic alkyl-groups from
the O6-position of guanine, which could otherwise lead to G-A
transitions after DNA replication (Gerson, 2004). As a result, it
inhibits the killing of tumour cells by alkylating agents.
Hypermethylation of the MGMT promoter and associated loss of
expression correlates with response to temozolamide and BCNU in
primary gliomas (Esteller et al, 2000; Paz et al, 2004) and is an
independent predictor of overall and progression-free survival in
patients with diffuse large B-cell lymphoma treated with cyclophos-
phamide-containing regimens (Esteller et al, 2002). Importantly,
the methylation status of MGMT in gliomas at presentation does
not correlate with the clinical response when temozolamide is used
at relapse, demonstrating that the value of biomarkers may depend
on when during tumour progression or treatment they are
measured.
There is thus growing evidence that CpG island methylation of
genes with a known direct involvement in drug responses has
a potential role in predicting clinical outcome following chemo-
therapy. However, there is a need for studies to investigate the
potential to use methylation patterns of known or unknown genes
to identify which patients may benefit from particular chemother-
apeutic regimes or biological therapies. Given the potential of
opposing effects depending on which genes are methylated, it is
vital to examine whether particular methylation events are
dominant in conferring resistance. Methods that allow genome-
wide analysis of methylation patterns may be particularly
important for these types of study (Box 1). In a study of late-
stage ovarian tumours, increased methylation of a subset of CpG
islands significantly correlated with worse clinical outcome, as
defined by the time to clinical disease recurrence after chemo-
therapy (Wei et al, 2002). However in a study of 106 stage III/IV
ovarian cancers, methylation of at least one of a group of genes
involved in DNA repair/drug detoxification (BRCA1, GSTP1,
MGMT) was associated with improved response to chemotherapy
(Teodoridis et al, 2005).
Large-scale analysis of methylation patterns and correlation
with response is intrinsically susceptible to the problems of
multiple testing. This can be reduced by grouping genes into
predefined groups according to a biological hypothesis such as
grouping those with similar biological roles or within the same
pathway, on the assumption that disruption of any one gene within
a pathway or group will disrupt the functioning of that cellular
response. This is undoubtedly an oversimplification and the
approach will need to be refined as more sophisticated molecular
interaction maps and networks are developed (Pommier et al,
2004). An alternative approach will be to use supervised search
algorithms that efficiently search array data to identify clusters
that associate with clinical outcome (for instance, see Bair and
Tibshirani, 2004).
OVERCOMING EPIGENETIC RESISTANCE
MECHANISMS
Epigenetic modifications require active mechanisms of main-
tenance and so unlike genetic modifications, they are amenable to
pharmacological manipulation. 5-Azacytidine and its deoxyribose
analogue, 5-aza-20-deoxycytidine (decitabine), have been used for
many years to inhibit DNA methyltransferases and reverse DNA
methylation in tissue culture (Brown and Plumb, 2004). These
demethylating agents have been shown to reactivate expression of
numerous methylation-silenced genes. Decitabine has clinical
activity as a single agent in myelodysplastic syndrome (MDS),
CML and AML (Issa et al, 2004). Its activity in solid tumours as a
single agent has so far been disappointing. However, it may have a
role in sensitising tumours to other anticancer therapies by
causing re-expression of genes involved in drug sensitivity (Plumb
et al, 2000). In vitro the differentiating effect of decitabine in
cultured fibroblasts has a narrow dose window with a loss of action
at high doses possibly caused by cytotoxicity as a result of its
incorporation into DNA (Taylor and Jones, 1979). It may,
therefore, be more appropriate to use demethylating agents at
concentrations below the maximally tolerated dose, but still at a
level where they are known to cause demethylation and induce
gene re-expression. Consistent with this, a low dose schedule
appeared to be superior to schedules using higher doses in a study
of haematological malignancies (Issa et al, 2004). This has the
advantage of reducing the bone marrow toxicity of decitabine and
making it easier to combine it with conventional cytotoxics.
Histone deacetylase activity is important in the transcriptional
repression of methylated sequences (Fischle et al, 2003). The
combination of DNA-demethylating agents and HDAC inhibitors
causes synergistic re-expression of epigenetically silenced genes
(Cameron et al, 1999). It also produces synergistic antitumour
effects and increased sensitivity to chemotherapeutic agents in cell
line models (Boivin et al, 2002). The potential of this approach is
now being assessed in clinical trials (http://www.clinicaltrials.gov/
ct/show/NCT00114257).
Histone deacetylase inhibitors and demethylating agents, such
as decitabine, will affect the expression of multiple genes. Given
the potential for opposing effects on chemosensitivity when
different genes are re-expressed, it could be argued that we need
to develop epigenetic therapies that are more gene specific in their
mechanism of action. However, if we consider drug resistance to
be a polygenic process, then there may be advantages to a
multitargeted approach. This implies that some patients may
benefit from epigenetic therapies as chemosensitisers, while others
will not or may even do worse. Therefore, it will be vital to identify
patterns of methylation that reliably predict for response to
treatment and whether particular methylation events are dominant
in conferring resistance. In order to do this we need robust
clinically applicable technology to determine methylation patterns
in tumours both at presentation and at relapse. There is also a need
for pharmacodynamic markers of response to demethylating
agents. Demethylation can be monitored on a whole-genome level
or by analysis of individual genes (Lyko and Brown, 2005). It has
been shown that genomic DNA methylation levels are decreased in
peripheral blood mononuclear cells from xenograft tumour-
bearing mice treated with 5-aza-20-deoxycytidine (Plumb et al,
2000). This decrease closely coincided with the demethylation of
the hMLH1 promoter in the tumours, which indicates that
peripheral blood can serve as a surrogate tissue for determining
pharmacodynamic characteristics of DNMT inhibitors. However,
although demethylation of individual genes such as p15 has been
demonstrated in clinical trials (Daskalakis et al, 2002), the
Epigenetics driving polygenic clinical drug resistance
RM Glasspool et al
1090
British Journal of Cancer (2006) 94(8), 1087–1092 & 2006 Cancer Research UKprognostic value of these methylation changes remains to be
established.
CONCLUSIONS
Aberrant epigenetic regulation, such as DNA methylation of CpG
islands, occurs at many genes and in all cancers. CpG island
methylation is a potentially important driving force both for
tumorogenesis and for drug resistance. The use of demethylating
agents and HDAC inhibitors offers the potential to favourably alter
the gene expression profile of tumours to cause tumour cell death
and increased apoptotic response to established cytotoxic agents.
However, we need to identify and evaluate in greater detail the
epigenetic characteristics of tumours that predict for lack of
response to conventional treatment, so as to identify those patients
who may particularly benefit from an epigenetic approach. The
polygenic nature of these changes will make this challenging.
Towards this objective, genome-wide CpG island methylation of
patients’ tumours can be examined, as well as detailed character-
isation of methylation of individual CpG islands. Examination of
tumour DNA released into body fluids may make the large
numbers required for these analyses more feasible. These assays
need to be conducted in an appropriate quality assured manner
and their utility properly evaluated in prospective, randomised
trials. Although the epigenetic therapies now undergoing clinical
evaluations show promise, there is a need for further agents, which
are more specific for epigenetic targets. This need not equate to
more gene specificity, but rather to less nonspecific toxic effects
such as the myelosuppression seen with decitabine which may be
the result of direct cytotoxic effects of decitabine rather than
demethylation. The clinical development of epigenetic therapies
will require the development of surrogate pharmacodynamic
markers to assess whether these therapies are having their desired
pharmacodynamic effect (e.g. global or gene-specific demethyla-
tion) and then whether this translates into clinical benefit.
Epigenetic pharmacodynamic markers can be used as novel end
points in early clinical trials allowing recommended doses to be
based on maximal biological effect rather than maximum tolerated
dose. Thus, such pharmacodynamic and predictive epigenetic
biomarkers, together with targeted drug development, will allow
rational and efficient evaluation of novel epigenetic therapies for
cancer treatment.
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